{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Genotype&page=21", "query": { "intervention": "Genotype", "page": 21 }, "page_size": 10 }, "pagination": { "page": 21, "page_size": 10, "total_count": 821, "total_pages": 83, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Genotype&page=22&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Genotype&page=20&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T00:53:18.369Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03383224", "title": "PRISM-GENOMICS-Smoking Cessation for Patients With Coronary Artery Disease Undergoing Cardiac Catheterization or Having a Heart Attack at Barnes Hospital in St. Louis Mo", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Coronary Artery Disease", "Smoking Cessation" ], "interventions": [ { "name": "genotype-guided therapy", "type": "OTHER" }, { "name": "Nicotine patch", "type": "DRUG" }, { "name": "Smoking cessation counseling", "type": "BEHAVIORAL" } ], "intervention_types": [ "OTHER", "DRUG", "BEHAVIORAL" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2015-07-21", "completion_date": "2025-07-21", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-10-19T00:53:18.369Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03383224" }, { "nct_id": "NCT07232355", "title": "Prevention of Cervical Cancer Using the Genotyping Screening and Same-day Self-sampling", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Human Papilloma Virus" ], "interventions": [], "intervention_types": [], "sponsor": "Atila Biosystems Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "30 Years", "maximum_age": "64 Years", "sex": "FEMALE", "summary": "30 Years to 64 Years · Female only" }, "enrollment_count": 5000, "start_date": "2023-08-24", "completion_date": "2026-06", "has_results": false, "last_update_posted_date": "2025-11-19", "last_synced_at": "2026-10-19T00:53:18.369Z", "location_count": 1, "location_summary": "Sunnyvale, California", "locations": [ { "city": "Sunnyvale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07232355" }, { "nct_id": "NCT01125189", "title": "Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus" ], "interventions": [ { "name": "Daclatasvir", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "peg-interferon alfa-2a", "type": "DRUG" }, { "name": "ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 558, "start_date": "2010-07", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2015-10-23", "last_synced_at": "2026-10-19T00:53:18.369Z", "location_count": 33, "location_summary": "Montgomery, Alabama • La Jolla, California • Los Angeles, California + 26 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01125189" }, { "nct_id": "NCT00839657", "title": "Clarification of Optimal Anticoagulation Through Genetics", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stroke", "Venous Thrombosis", "Atrial Fibrillation", "Atrial Flutter" ], "interventions": [ { "name": "Genotype-guided dosing algorithm for warfarin", "type": "BEHAVIORAL" }, { "name": "Clinical-guided dosing algorithm for warfarin", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1015, "start_date": "2009-09", "completion_date": "2013-11", "has_results": false, "last_update_posted_date": "2016-04-20", "last_synced_at": "2026-10-19T00:53:18.369Z", "location_count": 18, "location_summary": "Birmingham, Alabama • San Francisco, California • Gainesville, Florida + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00839657" }, { "nct_id": "NCT06972407", "title": "The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Genetic Predisposition", "Type2diabetes" ], "interventions": [ { "name": "Exendin 9-39", "type": "BIOLOGICAL" }, { "name": "Saline", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "25 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "25 Years to 70 Years" }, "enrollment_count": 80, "start_date": "2026-10-01", "completion_date": "2029-03-01", "has_results": false, "last_update_posted_date": "2026-01-30", "last_synced_at": "2026-10-19T00:53:18.369Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06972407" }, { "nct_id": "NCT01667731", "title": "Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C", "Human Immunodeficiency Virus" ], "interventions": [ { "name": "SOF", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 224, "start_date": "2012-07", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2014-11-21", "last_synced_at": "2026-10-19T00:53:18.369Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Coronado, California • Los Angeles, California + 23 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Coronado", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Lutherville", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01667731" }, { "nct_id": "NCT02127892", "title": "SCID Bu/Flu/ATG Study With T Cell Depletion", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Severe Combined Immunodeficiency" ], "interventions": [ { "name": "unrelated BM with T cell depletion", "type": "BIOLOGICAL" }, { "name": "unrelated cord blood", "type": "BIOLOGICAL" }, { "name": "haplo BM with T cell depletion", "type": "BIOLOGICAL" }, { "name": "unrelated PBSC with T cell depletion", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE" ], "sponsor": "Neena Kapoor, M.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 9, "start_date": "2007-01-02", "completion_date": "2016-08-01", "has_results": true, "last_update_posted_date": "2017-09-18", "last_synced_at": "2026-10-19T00:53:18.369Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02127892" }, { "nct_id": "NCT07373470", "title": "An Evaluation of the Impact of Pharmacist Comprehensive Medication Management With Pharmacogenomic Results to Improve Depression Outcomes in Community Pharmacies.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pharmacogenetics", "Depression - Major Depressive Disorder", "Pharmacogenomic Drug Interaction", "Community Pharmacy Services" ], "interventions": [ { "name": "Comprehensive medication management with PGx testing results", "type": "OTHER" }, { "name": "Usual Care", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2026-09-09", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-19T00:53:18.369Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07373470" }, { "nct_id": "NCT00462917", "title": "REVEAL III: Risk Evaluation and Education for Alzheimer's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Alzheimer Disease" ], "interventions": [ { "name": "Pleiotropic info, in-person disclosure", "type": "BEHAVIORAL" }, { "name": "AD-only info, in-person disclosure", "type": "BEHAVIORAL" }, { "name": "Pleiotropic info, phone disclosure", "type": "BEHAVIORAL" }, { "name": "AD-only info, phone disclosure", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 290, "start_date": "2007-03", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2018-10-23", "last_synced_at": "2026-10-19T00:53:18.369Z", "location_count": 4, "location_summary": "Washington D.C., District of Columbia • Boston, Massachusetts • Ann Arbor, Michigan + 1 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00462917" }, { "nct_id": "NCT02249182", "title": "Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus Infection" ], "interventions": [ { "name": "LDV/SOF", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "3 Years to 17 Years" }, "enrollment_count": 226, "start_date": "2014-11-05", "completion_date": "2018-08-24", "has_results": true, "last_update_posted_date": "2020-03-02", "last_synced_at": "2026-10-19T00:53:18.369Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02249182" } ] }